Immunotherapy and Asthma in Children

Research output: Contribution to journalReview article

Abstract

Allergen immunotherapy (AIT) is still the only disease-modifying treatment strategy for IgE-mediated allergic diseases, with consolidated evidence both in adults and children. AIT is effective in determining clinical improvement of allergic rhinitis and asthma, such as reduced symptoms, medication use, and improvement of quality of life, with a long-lasting effect after cessation of treatment. Results from recent clinical studies have implemented the evidence of effectiveness and safety of allergen immunotherapy for the treatment of allergic asthma, so that the current asthma guidelines now recommend sublingual immunotherapy as an add-on therapy for asthma in adults and adolescents with house dust mite allergy, allergic rhinitis, and exacerbations despite low-to-moderate dose ICS, with forced expiratory volume in 1 second more than 70% predicted. AIT may also reduce the risk of progression from allergic rhinitis to asthma in children and prevent the onset of new sensitizations, thus representing a potentially preventive method of treatment. The aim of this review is to present an updated overview of the clinical indications of AIT, with particular reference to pediatric asthma, of the mechanisms of clinical and immunological tolerance to allergens, and of the potential biomarkers predicting clinical response.

Original languageEnglish
Pages (from-to)231
JournalFrontiers in Pediatrics
Volume6
DOIs
Publication statusPublished - 2018

Fingerprint

Immunologic Desensitization
Immunotherapy
Asthma
Sublingual Immunotherapy
Pyroglyphidae
Withholding Treatment
Forced Expiratory Volume
Therapeutics
Allergens
Immunoglobulin E
Hypersensitivity
Biomarkers
Quality of Life
Guidelines
Pediatrics
Safety
Allergic Rhinitis

Cite this

Immunotherapy and Asthma in Children. / Tosca, Maria A; Licari, Amelia; Olcese, Roberta; Marseglia, Gianluigi; Sacco, Oliviero; Ciprandi, Giorgio.

In: Frontiers in Pediatrics, Vol. 6, 2018, p. 231.

Research output: Contribution to journalReview article

@article{4f458b69bedc47be9caa384366904bd9,
title = "Immunotherapy and Asthma in Children",
abstract = "Allergen immunotherapy (AIT) is still the only disease-modifying treatment strategy for IgE-mediated allergic diseases, with consolidated evidence both in adults and children. AIT is effective in determining clinical improvement of allergic rhinitis and asthma, such as reduced symptoms, medication use, and improvement of quality of life, with a long-lasting effect after cessation of treatment. Results from recent clinical studies have implemented the evidence of effectiveness and safety of allergen immunotherapy for the treatment of allergic asthma, so that the current asthma guidelines now recommend sublingual immunotherapy as an add-on therapy for asthma in adults and adolescents with house dust mite allergy, allergic rhinitis, and exacerbations despite low-to-moderate dose ICS, with forced expiratory volume in 1 second more than 70{\%} predicted. AIT may also reduce the risk of progression from allergic rhinitis to asthma in children and prevent the onset of new sensitizations, thus representing a potentially preventive method of treatment. The aim of this review is to present an updated overview of the clinical indications of AIT, with particular reference to pediatric asthma, of the mechanisms of clinical and immunological tolerance to allergens, and of the potential biomarkers predicting clinical response.",
author = "Tosca, {Maria A} and Amelia Licari and Roberta Olcese and Gianluigi Marseglia and Oliviero Sacco and Giorgio Ciprandi",
year = "2018",
doi = "10.3389/fped.2018.00231",
language = "English",
volume = "6",
pages = "231",
journal = "Frontiers in Pediatrics",
issn = "2296-2360",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Immunotherapy and Asthma in Children

AU - Tosca, Maria A

AU - Licari, Amelia

AU - Olcese, Roberta

AU - Marseglia, Gianluigi

AU - Sacco, Oliviero

AU - Ciprandi, Giorgio

PY - 2018

Y1 - 2018

N2 - Allergen immunotherapy (AIT) is still the only disease-modifying treatment strategy for IgE-mediated allergic diseases, with consolidated evidence both in adults and children. AIT is effective in determining clinical improvement of allergic rhinitis and asthma, such as reduced symptoms, medication use, and improvement of quality of life, with a long-lasting effect after cessation of treatment. Results from recent clinical studies have implemented the evidence of effectiveness and safety of allergen immunotherapy for the treatment of allergic asthma, so that the current asthma guidelines now recommend sublingual immunotherapy as an add-on therapy for asthma in adults and adolescents with house dust mite allergy, allergic rhinitis, and exacerbations despite low-to-moderate dose ICS, with forced expiratory volume in 1 second more than 70% predicted. AIT may also reduce the risk of progression from allergic rhinitis to asthma in children and prevent the onset of new sensitizations, thus representing a potentially preventive method of treatment. The aim of this review is to present an updated overview of the clinical indications of AIT, with particular reference to pediatric asthma, of the mechanisms of clinical and immunological tolerance to allergens, and of the potential biomarkers predicting clinical response.

AB - Allergen immunotherapy (AIT) is still the only disease-modifying treatment strategy for IgE-mediated allergic diseases, with consolidated evidence both in adults and children. AIT is effective in determining clinical improvement of allergic rhinitis and asthma, such as reduced symptoms, medication use, and improvement of quality of life, with a long-lasting effect after cessation of treatment. Results from recent clinical studies have implemented the evidence of effectiveness and safety of allergen immunotherapy for the treatment of allergic asthma, so that the current asthma guidelines now recommend sublingual immunotherapy as an add-on therapy for asthma in adults and adolescents with house dust mite allergy, allergic rhinitis, and exacerbations despite low-to-moderate dose ICS, with forced expiratory volume in 1 second more than 70% predicted. AIT may also reduce the risk of progression from allergic rhinitis to asthma in children and prevent the onset of new sensitizations, thus representing a potentially preventive method of treatment. The aim of this review is to present an updated overview of the clinical indications of AIT, with particular reference to pediatric asthma, of the mechanisms of clinical and immunological tolerance to allergens, and of the potential biomarkers predicting clinical response.

U2 - 10.3389/fped.2018.00231

DO - 10.3389/fped.2018.00231

M3 - Review article

C2 - 30186823

VL - 6

SP - 231

JO - Frontiers in Pediatrics

JF - Frontiers in Pediatrics

SN - 2296-2360

ER -